These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25223579)

  • 1. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
    Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
    Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
    Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
    J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masitinib is safe and effective for the treatment of canine mast cell tumors.
    Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
    J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
    Grant J; North S; Lanore D
    J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Masitinib" is safe and effective for the treatment of canine mast cell tumors.
    Gentilini F
    J Vet Intern Med; 2010; 24(1):6; author reply 7. PubMed ID: 20391634
    [No Abstract]   [Full Text] [Related]  

  • 7. Is lymph node metastasis of canine grade 2 MCTs justification for adjuvant therapy?
    Schulman FY
    Vet Comp Oncol; 2015 Jun; 13(2):151. PubMed ID: 25968074
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours.
    Donnelly L; Mullin C; Balko J; Goldschmidt M; Krick E; Hume C; Brown DC; Sorenmo K
    Vet Comp Oncol; 2015 Mar; 13(1):70-6. PubMed ID: 23451809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumours and early nodal metastasis undergoing surgery.
    Marconato L; Stefanello D; Kiupel M; Finotello R; Polton G; Massari F; Ferrari R; Agnoli C; Capitani O; Giudice C; Aresu L; Vasconi ME; Rigillo A; Sabattini S
    Vet Comp Oncol; 2020 Sep; 18(3):409-415. PubMed ID: 31930651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of outcome and prognostic factors of subcutaneous mast cell tumours in dogs undergoing surgery with or without adjuvant treatment.
    Treggiari E; Valenti P; Porcellato I; Maresca G; Romanelli G
    Vet Comp Oncol; 2023 Sep; 21(3):437-446. PubMed ID: 37121954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
    Cooper M; Tsai X; Bennett P
    Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
    Thamm DH; Mauldin EA; Vail DM
    J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy.
    Tran CM; Moore AS; Frimberger AE
    Vet Comp Oncol; 2016 Sep; 14(3):252-62. PubMed ID: 24735412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional local therapy with primary re-excision or radiation therapy improves survival and local control after incomplete or close surgical excision of mast cell tumors in dogs.
    Kry KL; Boston SE
    Vet Surg; 2014 Feb; 43(2):182-9. PubMed ID: 24392683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
    Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
    BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
    Malone EK; Rassnick KM; Wakshlag JJ; Russell DS; Al-Sarraf R; Ruslander DM; Johnson CS; Trump DL
    Vet Comp Oncol; 2010 Sep; 8(3):209-20. PubMed ID: 20691028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
    Thamm DH; Turek MM; Vail DM
    J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases.
    O'Connell K; Thomson M
    Vet Comp Oncol; 2013 Mar; 11(1):51-62. PubMed ID: 22235766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of dogs undergoing surgical resection of mast cell tumors and soft tissue sarcomas: A prospective 2-year-long study.
    Milovancev M; Townsend KL; Tuohy JL; Gorman E; Bracha S; Curran KM; Russell DS
    Vet Surg; 2020 Jan; 49(1):96-105. PubMed ID: 31044443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.